The iron-loaded gerbil model revisited: Effects of deferoxamine and deferiprone treatment

Journal of Laboratory and Clinical Medicine

Volumn 139, Issue 1, 2002, Pages 50-58

  Hershko, C ^a,b   Link, G ^a,b   Konijn, A M ^a,b   Huerta, M ^a,b   Rosenmann, E ^a,b   Reinus, C ^a,b  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; IRON CHELATING AGENT; PYRIDONE DERIVATIVE;

ANIMAL; ARTICLE; DISEASE MODEL; FEMALE; GERBIL; HEART MUSCLE; IRON OVERLOAD; LIVER; METABOLISM; PATHOLOGY;

ANIMALS; DEFEROXAMINE; DISEASE MODELS, ANIMAL; FEMALE; GERBILLINAE; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MYOCARDIUM; PYRIDONES;

EID: 0036008996     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1067/mlc.2002.120364     Document Type: Article

References (33)

1. Results of long-term iron chelating therapy
2. Survival of medically treated patients with homozygous β thalassemia
3. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major
4. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients
5. Iron-chelation therapy with oral deferiprone in patients with thalassemia major
6. Results of long-term deferiprone (L1) therapy: A report by the International Study Group on Oral Iron Chelators
7. Safety profile of the oral iron chelator deferiprone: A multicentre study
8. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients
9. Absence of deferiprone-induced hepatic fibrosis: A multi-center study
10. The development of hydroxypyridin-4-ones as orally active iron chelators
11. Potentiation of iron accumulation in cardiac myocytes during the treatment of iron overload in gerbils with the hydroxypyridone iron chelator CP94
12. Contrasting interspecies efficacy and toxicology of 1, 2-diethyl-3-hydroxypyrid-4-one, CP94, relates to differing metabolism of the iron chelating site
13. Urinary metabolic profiles in human and rat of 1.2-dimethyl and 1, 2-diethyl-substituted 3-hydroxypyrid-4-ones
14. A simple technique for measuring storage iron concentrations in formalinized liver samples
15. Cardioprotective effect of alpha-tocopherol, ascorbate, deferoxamine, and deferiprone: Mitochondrial function in cultured, iron-loaded heart cells
16. Exact probability test
17. Nonparametric estimation from incomplete observations
18. A unique rodent model for both the cardiotoxic and hepatotoxic effects of prolonged iron overload
19. Rapid induction of hepatic fibrosis in the gerbil after the parenterai administration of iron-dextran complex
20. Molecular and cellular aspects of iron-induced hepatic cirrhosis in rodents
21. Hepatic stellate cells are not subjected to oxidant stress during iron-induced fibrogenesis in rodents
22. Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocytes. Implications for the arrhythmogenesis of human siderotic heart disease
23. Deferiprone. A review of its clinical potential in iron overload in β-thalassaemia major and other transfusion-dependent diseases
24. Iron chelators for thalassaemia
25. Annotation. Oral iron chelation therapy for thalassaemia: An uncertain scene
26. The histogenesis of hepatoma occurring spontaneously in a strain of sand rats (Psammomys obesus)
27. Protective effect of iron chelators: Comparative studies with deferoxamine and deferiprone
28. The iron chelator L1 potentiates oxidative damage in iron-loaded liver cells
29. Liver iron depletion and toxicity of the iron chelator deferiprone (L1, CP20) in the guinea pig
30. Hepatic iron overload in pathogen-free gerbils does not result in bridging fibrosis or cirrhosis
31. Hepatic fibrosis and iron accumulation due to endotoxin induced hemorrhage in the gerbil